Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: Potential relevance to statin-associated dysglycemia

Journal of Lipid Research

Volumn 56, Issue 12, 2015, Pages 2381-2392

  Meikle, Peter J ^a   Wong, Gerard ^a   Tan, Ricardo ^a   Giral, Philippe ^b   Robillard, Paul ^b   Orsoni, Alexina ^b   Hounslow, Neil ^c   Magliano, Dianna J ^a   Shaw, Jonathan E ^a   Curran, Joanne E ^d   Blangero, John ^d   Kingwell, Bronwyn A ^a   Chapman, M John ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b INSERM   (France)

^c Kowa Research Europe Ltd   (United Kingdom)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cholesterol ; Lipidomics ; Metabolic syndrome; Obesity ; Omega 3 fatty acids ; Pitavastatin ; Plasmalogens

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPIDOME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; CHOLESTEROL; LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DYSGLYCEMIA; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID ANALYSIS; LIPIDOMICS; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; ATHEROSCLEROSIS; BLOOD; CHEMICALLY INDUCED; DISORDERS OF CARBOHYDRATE METABOLISM; DYSLIPIDEMIAS; FEMALE; MIDDLE AGED;

ADULT; AGED; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; GLUCOSE METABOLISM DISORDERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TRIGLYCERIDES;

EID: 84948971422     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P061143     Document Type: Article

References (42)

1. Baigent , C. , L. Blackwell , J. Emberson , L. E. Holland , C. Reith , N. Bhala , R. Peto , E. H. Barnes , A. Keech , J. Simes , et al . 2010 . Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet . 376 : 1670 - 1681 .
2. Nicholls , S. J. , C. M. Ballantyne , P. J. Barter , M. J. Chapman , R. M. Erbel , P. Libby , J. S. Raichlen , K. Uno , M. Borgman , K. Wolski , et al . 2011 . Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 365 : 2078 - 2087 .
3. Sposito , A. C. , and M. J. Chapman . 2002 . Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler. Thromb. Vasc. Biol. 22 : 1524 - 1534 .
4. Kashani , A. , C. O. Phillips , J. M. Foody , Y. Wang , S. Mangalmurti , D. T. Ko , and H. M. Krumholz . 2006 . Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation . 114 : 2788 - 2797 .
5. Ridker , P. M. , A. Pradhan , J. G. MacFadyen , P. Libby , and R. J. Glynn . 2012 . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet . 380 : 565 - 571 .
6. Waters , D. D. , J. E. Ho , S. M. Boekholdt , D. A. DeMicco , J. J. Kastelein , M. Messig , A. Breazna , and T. R. Pedersen . 2013 . Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J. Am. Coll. Cardiol. 61 : 148 - 152 .
7. Alberti , G. , P. Zimmet , J. Shaw , and S. M. Grundy . 2006 . The IDF consensus worldwide definition of the metabolic sybdrome. IDF Communications. Accessed October 31, 2015 at http://www.idf.org/ webdata/docs/IDF-Meta-def-final.pdf.
8. Chapman , M. J. , H. N. Ginsberg , P. Amarenco , F. Andreotti , J. Boren , A. L. Catapano , O. S. Descamps , E. Fisher , P. T. Kovanen , J. A. Kuivenhoven , et al . 2011 . Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32 : 1345 - 1361 .
9. Li , N. , J. Fu , D. P. Koonen , J. A. Kuivenhoven , H. Snieder , and M. H. Hofker . 2014 . Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance? Atherosclerosis . 233 : 130 - 138 .
10. Cederberg , H. , A. Stancakova , N. Yaluri , S. Modi , J. Kuusisto , and M. Laakso . 2015 . Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia . 58 : 1109 - 1117 .
11. Swerdlow , D. I. , D. Preiss , K. B. Kuchenbaecker , M. V. Holmes , J. E. Engmann , T. Shah , R. Sofat , S. Stender , P. C. Johnson , R. A. Scott , et al . 2015 . HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet . 385 : 351 - 361 .
12. Naci , H. , J. Brugts , and T. Ades . 2013 . Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246,955 participants from 135 randomized, controlled trials. Circ. Cardiovasc. Qual. Outcomes . 6 : 390 - 399 .
13. Navarese , E. P. , A. Buffon , F. Andreotti , M. Kozinski , N. Welton , T. Fabiszak , S. Caputo , G. Grzesk , A. Kubica , I. Swiatkiewicz , et al . 2013 . Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am. J. Cardiol. 111 : 1123 - 1130 .
14. Sattar , N. A. , H. Ginsberg , K. Ray , M. J. Chapman , M. Arca , M. Averna , D. J. Betteridge , D. Bhatnagar , E. Bilianou , R. Carmena , et al . 2014 . The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler. Suppl. 15 : 1 - 15 .
15. Vallejo-Vaz , A. J. , S. R. Kondapally Seshasai , K. Kurogi , I. Michishita , T. Nozue , S. Sugiyama , S. Tsimikas , H. Yoshida , and K. K. Ray . 2015 . Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis . 241 : 409 - 418 .
16. Chapman , M. J. , W. Le Goff , M. Guerin , and A. Kontush . 2010 . Cholesteryl ester transfer protein: at the heart of the action of lipidmodulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J. 31 : 149 - 164 .
17. Meikle , P. J. , G. Wong , C. K. Barlow , J. M. Weir , M. A. Greeve , G. L. Macintosh , L. Almasy , A. G. Comuzzie , M. C. Mahaney , A. Kowalczyk , et al . 2013 . Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS One . 8 : e74341 .
18. Ståhlman , M. , B. Fagerberg , M. Adiels , K. Ekroos , J. M. Chapman , A. Kontush , and J. Boren . 2013 . Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles. Biochim. Biophys. Acta . 1831 : 1609 - 1617 .
19. Boon , J. , A. J. Hoy , R. Stark , R. D. Brown , R. C. Meex , D. C. Henstridge , S. Schenk , P. J. Meikle , J. F. Horowitz , B. A. Kingwell , et al . 2013 . Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes . 62 : 401 - 410 .
20. de Mello , V. D. , M. Lankinen , U. Schwab , M. Kolehmainen , S. Lehto , T. Seppanen-Laakso , M. Oresic , L. Pulkkinen , M. Uusitupa , and A. T. Erkkila . 2009 . Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia . 52 : 2612 - 2615 .
21. Meikle , P. J. , G. Wong , C. K. Barlow , and B. A. Kingwell . 2014 . Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacol. Ther. 143 : 12 - 23 .
22. Meikle , P. J. , G. Wong , D. Tsorotes , C. K. Barlow , J. M. Weir , M. J. Christopher , G. L. MacIntosh , B. Goudey , L. Stern , A. Kowalczyk , et al . 2011 . Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 31 : 2723 - 2732 .
23. Chapman , M. J. , A. Orsoni , P. Robillard , N. Hounslow , C. A. Sponseller , and P. Giral . 2014 . Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr. Med. Res. Opin. 30 : 775 - 784 .
24. Kontush , A. , S. Chantepie , and M. J. Chapman . 2003 . Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23 : 1881 - 1888 .
25. Zerrad-Saadi , A. , P. Therond , S. Chantepie , M. Couturier , K. A. Rye , M. J. Chapman , and A. Kontush . 2009 . HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 29 : 2169 - 2175 .
26. Weir , J. M. , G. Wong , C. K. Barlow , M. A. Greeve , A. Kowalczyk , L. Almasy , A. G. Comuzzie , M. C. Mahaney , J. B. Jowett , J. Shaw , et al . 2013 . Plasma lipid profiling in a large population-based cohort. J. Lipid Res. 54 : 2898 - 2908 .
27. Dunstan , D. W. , P. Z. Zimmet , T. A. Welborn , A. J. Cameron , J. Shaw , M. de Courten , D. Jolley , and D. J. McCarty . 2002 . The Australian Diabetes, Obesity and Lifestyle study (AusDiab)-methods and response rates. Diabetes Res. Clin. Pract. 57 : 119 - 129 .
28. Mitchell , B. D. , C. M. Kammerer , J. Blangero , M. C. Mahaney , D. L. Rainwater , B. Dyke , J. E. Hixson , R. D. Henkel , R. M. Sharp , A. G. Comuzzie , et al . 1996 . Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans. The San Antonio Family Heart Study. Circulation . 94 : 2159 - 2170 .
29. Hansel , B. , P. Giral , E. Nobecourt , S. Chantepie , E. Bruckert , M. J. Chapman , and A. Kontush . 2004 . Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 89 : 4963 - 4971 .
30. Gayoso-Diz , P. , A. Otero-Gonzalez , M. X. Rodriguez-Alvarez , F. Gude , F. Garcia , A. De Francisco , and A. G. Quintela . 2013 . Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr. Disord. 13 : 47 .
31. Barter , P. J. , G. Brandrup-Wognsen , M. K. Palmer , and S. J. Nicholls . 2010 . Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J. Lipid Res. 51 : 1546 - 1553 .
32. Nelson , J. C. , X. C. Jiang , I. Tabas , A. Tall , and S. Shea . 2006 . Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am. J. Epidemiol. 163 : 903 - 912 .
33. Fournier , N. , J. L. Paul , V. Atger , A. Cogny , T. Soni , M. de la Llera- Moya , G. Rothblat , and N. Moatti . 1997 . HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler. Thromb. Vasc. Biol. 17 : 2685 - 2691 .
34. Kontush , A. , P. Therond , A. Zerrad , M. Couturier , A. Negre- Salvayre , J. A. de Souza , S. Chantepie , and M. J. Chapman . 2007 . Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 27 : 1843 - 1849 .
35. Würtz , P. , A. S. Havulinna , P. Soininen , T. Tynkkynen , D. Prieto- Merino , T. Tillin , A. Ghorbani , A. Artati , Q. Wang , M. Tiainen , et al . 2015 . Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation . 131 : 774 - 785 .
36. Demetz , E. , A. Schroll , K. Auer , C. Heim , J. R. Patsch , P. Eller , M. Theurl , I. Theurl , M. Theurl , M. Seifert , et al . 2014 . The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metab. 20 : 787 - 798 .
37. Jürgens , G. , A. Fell , G. Ledinski , Q. Chen , and F. Paltauf . 1995 . Delay of copper-catalyzed oxidation of low density lipoprotein by in vitro enrichment with choline or ethanolamine plasmalogens. Chem. Phys. Lipids . 77 : 25 - 31 .
38. Mankidy , R. , P. W. Ahiahonu , H. Ma , D. Jayasinghe , S. A. Ritchie , M. A. Khan , K. K. Su-Myat , P. L. Wood , and D. B. Goodenowe . 2010 . Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study. Lipids Health Dis. 9 : 62 .
39. Marigny , K. , F. Pedrono , C. A. Martin-Chouly , H. Youmine , B. Saiag , and A. B. Legrand . 2002 . Modulation of endothelial permeability by 1-O-alkylglycerols. Acta Physiol. Scand. 176 : 263 - 268 .
40. Pynn , C. J. , N. G. Henderson , H. Clark , G. Koster , W. Bernhard , and A. D. Postle . 2011 . Specificity and rate of human and mouse liver and plasma phosphatidylcholine synthesis analyzed in vivo. J. Lipid Res. 52 : 399 - 407 .
41. Vance , D. E. 2013 . Physiological roles of phosphatidylethanolamine N-methyltransferase. Biochim. Biophys. Acta . 1831 : 626 - 632 .
42. Reiner , Z. , A. L. Catapano , G. De Backer , I. Graham , M. R. Taskinen , O. Wiklund , S. Agewall , E. Alegria , M. J. Chapman , P. Durrington , et al . 2011 . ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32 : 1769 - 1818 .